Propranolol
- Generic Name
- Propranolol
- Brand Names
- Hemangeol, Hemangiol, Inderal, Innopran
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21NO2
- CAS Number
- 525-66-6
- Unique Ingredient Identifier
- 9Y8NXQ24VQ
- Background
Propranolol is a racemic mixture of 2 enantiomers where the S(-)-enantiomer has approximately 100 times the binding affinity for beta adrenergic receptors. Propranolol is used to treat a number of conditions but most commonly is used for hypertension.
Propranolol was granted FDA approval on 13 November 1967.
- Indication
Propranolol is indicated to treat hypertension. Propranolol is also indicated to treat angina pectoris due to coronary atherosclerosis, atrial fibrillation, myocardial infarction, migraine, essential tremor, hypertrophic subaortic stenosis, pheochromocytoma, and proliferating infantile hemangioma.
- Associated Conditions
- Akathisia caused by antipsychotic use, Angina Pectoris, Atrial Fibrillation, Cardiovascular Mortality, Essential Tremor, Gastroesophageal variceal hemorrhage prophylaxis, Hemangiomas, Hypertension, Migraine, Myocardial Infarction, Obstructive Hypertrophic Cardiomyopathy, Performance Anxiety, Pheochromocytoma, Proliferating Infantile Hemangioma, Supraventricular Arrhythmias, Tachyarrhythmia caused by Digitalis intoxication, Tachyarrhythmia caused by catecholamine excess, Thyroid Crisis, Thyrotoxicosis, Tremor caused by lithium, Ventricular Tachycardia (VT)
- Associated Therapies
- -
Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers
- First Posted Date
- 2014-04-04
- Last Posted Date
- 2018-01-23
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 2
- Registration Number
- NCT02104011
- Locations
- 🇫🇷
Nephrology department, Bordeaux, France
Study of Arm and Putter Movement in Golfers With Golfer's Cramp
- Conditions
- Interventions
- First Posted Date
- 2014-01-10
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 38
- Registration Number
- NCT02032758
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Propanolol and Red Cell Adhesion Non-asthmatic Children Sickle Cell Disease
- First Posted Date
- 2013-12-16
- Last Posted Date
- 2017-06-08
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 9
- Registration Number
- NCT02012777
- Locations
- 🇺🇸
University of Miami, Miami, Florida, United States
Modafinil and Cognitive Function in POTS
- Conditions
- Interventions
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01988883
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
Establishing and Eliminating Cue-drug Associations in Human Cocaine Addiction
- Conditions
- Interventions
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2020-03-02
- Lead Sponsor
- Yale University
- Target Recruit Count
- 6
- Registration Number
- NCT01978457
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices
- Conditions
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 200
- Registration Number
- NCT01970748
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan
Propranolol in Severely Burned Children
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2019-09-24
- Target Recruit Count
- 63
- Registration Number
- NCT01957449
- Locations
- 🇺🇸
Shriners Hospitals for Children, Galveston, Texas, United States
Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2024-10-16
- Target Recruit Count
- 47
- Registration Number
- NCT01950520
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma
- First Posted Date
- 2013-07-26
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT01908972
- Locations
- 🇰🇷
Seould National University Hospital, Seoul, Korea, Republic of
Feasibility - Beta Adrenergic Blockade (BB) in Cervical Cancer (CX)
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2021-10-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01902966
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon B. Johnson General Hospital (LBJ), Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.